The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Bladder Cancer Targeted Drug Market Research Report 2025
Synopsis
Bladder cancer is a disease in which malignant (cancer) cells form in the tissues of the bladder. Targeted therapy is a treatment that targets the cancer’s specific genes, proteins, or the tissue environment that contributes to cancer growth and survival. This type of treatment blocks the growth and spread of cancer cells and tries to limit damage to healthy cells.
The global Bladder Cancer Targeted Drug market was valued at US$ 758 million in 2023 and is anticipated to reach US$ 1414.2 million by 2030, witnessing a CAGR of 9.2% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Bladder Cancer Targeted Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Bladder Cancer Targeted Drug.
Report Scope
The Bladder Cancer Targeted Drug market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Bladder Cancer Targeted Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Bladder Cancer Targeted Drug companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Pfizer
Merck KGaA
Roche
Astellas
Janssen Biotech
Bristol-Myers Squibb
Merck & Co.
Gilead Sciences
Segment by Type
Atezolizumab (Tecentriq)
Avelumab (Bavencio)
Erdafitinib (Balversa)
Other
Segment by Application
Hospital
Retail Pharmacy
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Bladder Cancer Targeted Drug companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Bladder cancer is a disease in which malignant (cancer) cells form in the tissues of the bladder. Targeted therapy is a treatment that targets the cancer’s specific genes, proteins, or the tissue environment that contributes to cancer growth and survival. This type of treatment blocks the growth and spread of cancer cells and tries to limit damage to healthy cells.
The global Bladder Cancer Targeted Drug market was valued at US$ 758 million in 2023 and is anticipated to reach US$ 1414.2 million by 2030, witnessing a CAGR of 9.2% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Bladder Cancer Targeted Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Bladder Cancer Targeted Drug.
Report Scope
The Bladder Cancer Targeted Drug market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Bladder Cancer Targeted Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Bladder Cancer Targeted Drug companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Pfizer
Merck KGaA
Roche
Astellas
Janssen Biotech
Bristol-Myers Squibb
Merck & Co.
Gilead Sciences
Segment by Type
Atezolizumab (Tecentriq)
Avelumab (Bavencio)
Erdafitinib (Balversa)
Other
Segment by Application
Hospital
Retail Pharmacy
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Bladder Cancer Targeted Drug companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Bladder Cancer Targeted Drug Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Atezolizumab (Tecentriq)
1.2.3 Avelumab (Bavencio)
1.2.4 Erdafitinib (Balversa)
1.2.5 Other
1.3 Market by Application
1.3.1 Global Bladder Cancer Targeted Drug Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Retail Pharmacy
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Bladder Cancer Targeted Drug Market Perspective (2019-2030)
2.2 Bladder Cancer Targeted Drug Growth Trends by Region
2.2.1 Global Bladder Cancer Targeted Drug Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Bladder Cancer Targeted Drug Historic Market Size by Region (2019-2024)
2.2.3 Bladder Cancer Targeted Drug Forecasted Market Size by Region (2025-2030)
2.3 Bladder Cancer Targeted Drug Market Dynamics
2.3.1 Bladder Cancer Targeted Drug Industry Trends
2.3.2 Bladder Cancer Targeted Drug Market Drivers
2.3.3 Bladder Cancer Targeted Drug Market Challenges
2.3.4 Bladder Cancer Targeted Drug Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Bladder Cancer Targeted Drug Players by Revenue
3.1.1 Global Top Bladder Cancer Targeted Drug Players by Revenue (2019-2024)
3.1.2 Global Bladder Cancer Targeted Drug Revenue Market Share by Players (2019-2024)
3.2 Global Bladder Cancer Targeted Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Bladder Cancer Targeted Drug Revenue
3.4 Global Bladder Cancer Targeted Drug Market Concentration Ratio
3.4.1 Global Bladder Cancer Targeted Drug Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Bladder Cancer Targeted Drug Revenue in 2023
3.5 Bladder Cancer Targeted Drug Key Players Head office and Area Served
3.6 Key Players Bladder Cancer Targeted Drug Product Solution and Service
3.7 Date of Enter into Bladder Cancer Targeted Drug Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Bladder Cancer Targeted Drug Breakdown Data by Type
4.1 Global Bladder Cancer Targeted Drug Historic Market Size by Type (2019-2024)
4.2 Global Bladder Cancer Targeted Drug Forecasted Market Size by Type (2025-2030)
5 Bladder Cancer Targeted Drug Breakdown Data by Application
5.1 Global Bladder Cancer Targeted Drug Historic Market Size by Application (2019-2024)
5.2 Global Bladder Cancer Targeted Drug Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Bladder Cancer Targeted Drug Market Size (2019-2030)
6.2 North America Bladder Cancer Targeted Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Bladder Cancer Targeted Drug Market Size by Country (2019-2024)
6.4 North America Bladder Cancer Targeted Drug Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Bladder Cancer Targeted Drug Market Size (2019-2030)
7.2 Europe Bladder Cancer Targeted Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Bladder Cancer Targeted Drug Market Size by Country (2019-2024)
7.4 Europe Bladder Cancer Targeted Drug Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Bladder Cancer Targeted Drug Market Size (2019-2030)
8.2 Asia-Pacific Bladder Cancer Targeted Drug Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Bladder Cancer Targeted Drug Market Size by Region (2019-2024)
8.4 Asia-Pacific Bladder Cancer Targeted Drug Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Bladder Cancer Targeted Drug Market Size (2019-2030)
9.2 Latin America Bladder Cancer Targeted Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Bladder Cancer Targeted Drug Market Size by Country (2019-2024)
9.4 Latin America Bladder Cancer Targeted Drug Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Bladder Cancer Targeted Drug Market Size (2019-2030)
10.2 Middle East & Africa Bladder Cancer Targeted Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Bladder Cancer Targeted Drug Market Size by Country (2019-2024)
10.4 Middle East & Africa Bladder Cancer Targeted Drug Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Detail
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Bladder Cancer Targeted Drug Introduction
11.1.4 Pfizer Revenue in Bladder Cancer Targeted Drug Business (2019-2024)
11.1.5 Pfizer Recent Development
11.2 Merck KGaA
11.2.1 Merck KGaA Company Detail
11.2.2 Merck KGaA Business Overview
11.2.3 Merck KGaA Bladder Cancer Targeted Drug Introduction
11.2.4 Merck KGaA Revenue in Bladder Cancer Targeted Drug Business (2019-2024)
11.2.5 Merck KGaA Recent Development
11.3 Roche
11.3.1 Roche Company Detail
11.3.2 Roche Business Overview
11.3.3 Roche Bladder Cancer Targeted Drug Introduction
11.3.4 Roche Revenue in Bladder Cancer Targeted Drug Business (2019-2024)
11.3.5 Roche Recent Development
11.4 Astellas
11.4.1 Astellas Company Detail
11.4.2 Astellas Business Overview
11.4.3 Astellas Bladder Cancer Targeted Drug Introduction
11.4.4 Astellas Revenue in Bladder Cancer Targeted Drug Business (2019-2024)
11.4.5 Astellas Recent Development
11.5 Janssen Biotech
11.5.1 Janssen Biotech Company Detail
11.5.2 Janssen Biotech Business Overview
11.5.3 Janssen Biotech Bladder Cancer Targeted Drug Introduction
11.5.4 Janssen Biotech Revenue in Bladder Cancer Targeted Drug Business (2019-2024)
11.5.5 Janssen Biotech Recent Development
11.6 Bristol-Myers Squibb
11.6.1 Bristol-Myers Squibb Company Detail
11.6.2 Bristol-Myers Squibb Business Overview
11.6.3 Bristol-Myers Squibb Bladder Cancer Targeted Drug Introduction
11.6.4 Bristol-Myers Squibb Revenue in Bladder Cancer Targeted Drug Business (2019-2024)
11.6.5 Bristol-Myers Squibb Recent Development
11.7 Merck & Co.
11.7.1 Merck & Co. Company Detail
11.7.2 Merck & Co. Business Overview
11.7.3 Merck & Co. Bladder Cancer Targeted Drug Introduction
11.7.4 Merck & Co. Revenue in Bladder Cancer Targeted Drug Business (2019-2024)
11.7.5 Merck & Co. Recent Development
11.8 Gilead Sciences
11.8.1 Gilead Sciences Company Detail
11.8.2 Gilead Sciences Business Overview
11.8.3 Gilead Sciences Bladder Cancer Targeted Drug Introduction
11.8.4 Gilead Sciences Revenue in Bladder Cancer Targeted Drug Business (2019-2024)
11.8.5 Gilead Sciences Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Bladder Cancer Targeted Drug Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Atezolizumab (Tecentriq)
Table 3. Key Players of Avelumab (Bavencio)
Table 4. Key Players of Erdafitinib (Balversa)
Table 5. Key Players of Other
Table 6. Global Bladder Cancer Targeted Drug Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 7. Global Bladder Cancer Targeted Drug Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 8. Global Bladder Cancer Targeted Drug Market Size by Region (2019-2024) & (US$ Million)
Table 9. Global Bladder Cancer Targeted Drug Market Share by Region (2019-2024)
Table 10. Global Bladder Cancer Targeted Drug Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 11. Global Bladder Cancer Targeted Drug Market Share by Region (2025-2030)
Table 12. Bladder Cancer Targeted Drug Market Trends
Table 13. Bladder Cancer Targeted Drug Market Drivers
Table 14. Bladder Cancer Targeted Drug Market Challenges
Table 15. Bladder Cancer Targeted Drug Market Restraints
Table 16. Global Bladder Cancer Targeted Drug Revenue by Players (2019-2024) & (US$ Million)
Table 17. Global Bladder Cancer Targeted Drug Market Share by Players (2019-2024)
Table 18. Global Top Bladder Cancer Targeted Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Bladder Cancer Targeted Drug as of 2023)
Table 19. Ranking of Global Top Bladder Cancer Targeted Drug Companies by Revenue (US$ Million) in 2023
Table 20. Global 5 Largest Players Market Share by Bladder Cancer Targeted Drug Revenue (CR5 and HHI) & (2019-2024)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Bladder Cancer Targeted Drug Product Solution and Service
Table 23. Date of Enter into Bladder Cancer Targeted Drug Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Bladder Cancer Targeted Drug Market Size by Type (2019-2024) & (US$ Million)
Table 26. Global Bladder Cancer Targeted Drug Revenue Market Share by Type (2019-2024)
Table 27. Global Bladder Cancer Targeted Drug Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 28. Global Bladder Cancer Targeted Drug Revenue Market Share by Type (2025-2030)
Table 29. Global Bladder Cancer Targeted Drug Market Size by Application (2019-2024) & (US$ Million)
Table 30. Global Bladder Cancer Targeted Drug Revenue Market Share by Application (2019-2024)
Table 31. Global Bladder Cancer Targeted Drug Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 32. Global Bladder Cancer Targeted Drug Revenue Market Share by Application (2025-2030)
Table 33. North America Bladder Cancer Targeted Drug Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 34. North America Bladder Cancer Targeted Drug Market Size by Country (2019-2024) & (US$ Million)
Table 35. North America Bladder Cancer Targeted Drug Market Size by Country (2025-2030) & (US$ Million)
Table 36. Europe Bladder Cancer Targeted Drug Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 37. Europe Bladder Cancer Targeted Drug Market Size by Country (2019-2024) & (US$ Million)
Table 38. Europe Bladder Cancer Targeted Drug Market Size by Country (2025-2030) & (US$ Million)
Table 39. Asia-Pacific Bladder Cancer Targeted Drug Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 40. Asia-Pacific Bladder Cancer Targeted Drug Market Size by Region (2019-2024) & (US$ Million)
Table 41. Asia-Pacific Bladder Cancer Targeted Drug Market Size by Region (2025-2030) & (US$ Million)
Table 42. Latin America Bladder Cancer Targeted Drug Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 43. Latin America Bladder Cancer Targeted Drug Market Size by Country (2019-2024) & (US$ Million)
Table 44. Latin America Bladder Cancer Targeted Drug Market Size by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Bladder Cancer Targeted Drug Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 46. Middle East & Africa Bladder Cancer Targeted Drug Market Size by Country (2019-2024) & (US$ Million)
Table 47. Middle East & Africa Bladder Cancer Targeted Drug Market Size by Country (2025-2030) & (US$ Million)
Table 48. Pfizer Company Detail
Table 49. Pfizer Business Overview
Table 50. Pfizer Bladder Cancer Targeted Drug Product
Table 51. Pfizer Revenue in Bladder Cancer Targeted Drug Business (2019-2024) & (US$ Million)
Table 52. Pfizer Recent Development
Table 53. Merck KGaA Company Detail
Table 54. Merck KGaA Business Overview
Table 55. Merck KGaA Bladder Cancer Targeted Drug Product
Table 56. Merck KGaA Revenue in Bladder Cancer Targeted Drug Business (2019-2024) & (US$ Million)
Table 57. Merck KGaA Recent Development
Table 58. Roche Company Detail
Table 59. Roche Business Overview
Table 60. Roche Bladder Cancer Targeted Drug Product
Table 61. Roche Revenue in Bladder Cancer Targeted Drug Business (2019-2024) & (US$ Million)
Table 62. Roche Recent Development
Table 63. Astellas Company Detail
Table 64. Astellas Business Overview
Table 65. Astellas Bladder Cancer Targeted Drug Product
Table 66. Astellas Revenue in Bladder Cancer Targeted Drug Business (2019-2024) & (US$ Million)
Table 67. Astellas Recent Development
Table 68. Janssen Biotech Company Detail
Table 69. Janssen Biotech Business Overview
Table 70. Janssen Biotech Bladder Cancer Targeted Drug Product
Table 71. Janssen Biotech Revenue in Bladder Cancer Targeted Drug Business (2019-2024) & (US$ Million)
Table 72. Janssen Biotech Recent Development
Table 73. Bristol-Myers Squibb Company Detail
Table 74. Bristol-Myers Squibb Business Overview
Table 75. Bristol-Myers Squibb Bladder Cancer Targeted Drug Product
Table 76. Bristol-Myers Squibb Revenue in Bladder Cancer Targeted Drug Business (2019-2024) & (US$ Million)
Table 77. Bristol-Myers Squibb Recent Development
Table 78. Merck & Co. Company Detail
Table 79. Merck & Co. Business Overview
Table 80. Merck & Co. Bladder Cancer Targeted Drug Product
Table 81. Merck & Co. Revenue in Bladder Cancer Targeted Drug Business (2019-2024) & (US$ Million)
Table 82. Merck & Co. Recent Development
Table 83. Gilead Sciences Company Detail
Table 84. Gilead Sciences Business Overview
Table 85. Gilead Sciences Bladder Cancer Targeted Drug Product
Table 86. Gilead Sciences Revenue in Bladder Cancer Targeted Drug Business (2019-2024) & (US$ Million)
Table 87. Gilead Sciences Recent Development
Table 88. Research Programs/Design for This Report
Table 89. Key Data Information from Secondary Sources
Table 90. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Bladder Cancer Targeted Drug Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Bladder Cancer Targeted Drug Market Share by Type: 2023 VS 2030
Figure 3. Atezolizumab (Tecentriq) Features
Figure 4. Avelumab (Bavencio) Features
Figure 5. Erdafitinib (Balversa) Features
Figure 6. Other Features
Figure 7. Global Bladder Cancer Targeted Drug Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 8. Global Bladder Cancer Targeted Drug Market Share by Application: 2023 VS 2030
Figure 9. Hospital Case Studies
Figure 10. Retail Pharmacy Case Studies
Figure 11. Other Case Studies
Figure 12. Bladder Cancer Targeted Drug Report Years Considered
Figure 13. Global Bladder Cancer Targeted Drug Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 14. Global Bladder Cancer Targeted Drug Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 15. Global Bladder Cancer Targeted Drug Market Share by Region: 2023 VS 2030
Figure 16. Global Bladder Cancer Targeted Drug Market Share by Players in 2023
Figure 17. Global Top Bladder Cancer Targeted Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Bladder Cancer Targeted Drug as of 2023)
Figure 18. The Top 10 and 5 Players Market Share by Bladder Cancer Targeted Drug Revenue in 2023
Figure 19. North America Bladder Cancer Targeted Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 20. North America Bladder Cancer Targeted Drug Market Share by Country (2019-2030)
Figure 21. United States Bladder Cancer Targeted Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. Canada Bladder Cancer Targeted Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. Europe Bladder Cancer Targeted Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. Europe Bladder Cancer Targeted Drug Market Share by Country (2019-2030)
Figure 25. Germany Bladder Cancer Targeted Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. France Bladder Cancer Targeted Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. U.K. Bladder Cancer Targeted Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Italy Bladder Cancer Targeted Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Russia Bladder Cancer Targeted Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Nordic Countries Bladder Cancer Targeted Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Asia-Pacific Bladder Cancer Targeted Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Asia-Pacific Bladder Cancer Targeted Drug Market Share by Region (2019-2030)
Figure 33. China Bladder Cancer Targeted Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Japan Bladder Cancer Targeted Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. South Korea Bladder Cancer Targeted Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Southeast Asia Bladder Cancer Targeted Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. India Bladder Cancer Targeted Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Australia Bladder Cancer Targeted Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Latin America Bladder Cancer Targeted Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Latin America Bladder Cancer Targeted Drug Market Share by Country (2019-2030)
Figure 41. Mexico Bladder Cancer Targeted Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Brazil Bladder Cancer Targeted Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Middle East & Africa Bladder Cancer Targeted Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Middle East & Africa Bladder Cancer Targeted Drug Market Share by Country (2019-2030)
Figure 45. Turkey Bladder Cancer Targeted Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Saudi Arabia Bladder Cancer Targeted Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 47. Pfizer Revenue Growth Rate in Bladder Cancer Targeted Drug Business (2019-2024)
Figure 48. Merck KGaA Revenue Growth Rate in Bladder Cancer Targeted Drug Business (2019-2024)
Figure 49. Roche Revenue Growth Rate in Bladder Cancer Targeted Drug Business (2019-2024)
Figure 50. Astellas Revenue Growth Rate in Bladder Cancer Targeted Drug Business (2019-2024)
Figure 51. Janssen Biotech Revenue Growth Rate in Bladder Cancer Targeted Drug Business (2019-2024)
Figure 52. Bristol-Myers Squibb Revenue Growth Rate in Bladder Cancer Targeted Drug Business (2019-2024)
Figure 53. Merck & Co. Revenue Growth Rate in Bladder Cancer Targeted Drug Business (2019-2024)
Figure 54. Gilead Sciences Revenue Growth Rate in Bladder Cancer Targeted Drug Business (2019-2024)
Figure 55. Bottom-up and Top-down Approaches for This Report
Figure 56. Data Triangulation
Figure 57. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
